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IMPORTANCE A critical bottleneck in clinical genomics is the mismatch between large
volumes of results and the availability of knowledgeable professionals to return them.
OBJECTIVE To test whether a web-based platform is noninferior to a genetic counselor for
educating patients about their carrier results from exome sequencing.
DESIGN, SETTING, AND PARTICIPANTS A randomized noninferiority trial conducted in a
longitudinal sequencing cohort at the National Institutes of Health from February 5, 2014, to
December 16, 2016, was used to compare the web-based platformwith a genetic counselor.
Among the 571 eligible participants, 1 to 7 heterozygous variants were identified in genes that
cause a phenotype that is recessively inherited. Surveys were administered after cohort
enrollment, immediately following trial education, and 1 month and 6months later to
primarily healthy postreproductive participants who expressed interest in learning their
carrier results. Both intention-to-treat and per-protocol analyses were applied.
INTERVENTIONS Aweb-based platform that integrated education on carrier results with
personal test results was designed to directly parallel disclosure education by a genetic
counselor. The sessions took amean (SD) time of 21 (10.6), and 27 (9.3) minutes, respectively.
MAIN OUTCOMES ANDMEASURES The primary outcomes and noninferioritymargins (δNI)
were knowledge (0 to 8, δNI = −1), test-specific distress (0 to 30, δNI = +1), and decisional
conflict (15 to 75, δNI = +6).
RESULTS After 462 participants (80.9%) provided consent and were randomized, all but 3
participants (n = 459) completed surveys following education and counseling; 398 (86.1%)
completed 1-month surveys and 392 (84.8%) completed 6-month surveys. Participants were
predominantly well-educated, non-Hispanic white, married parents; mean (SD) age was 63
(63.1) years and 246 (53.6%) weremen. The web platformwas noninferior to the genetic
counselor on outcomes assessed at 1 and 6months: knowledge (mean group difference,
−0.18; lower limit of 97.5% CI, −0.63; δNI = −1), test-specific distress (median group
difference, 0; upper limit of 97.5% CI, 0; δNI = +1), and decisional conflict about choosing to
learn results (mean group difference, 1.18; upper limit of 97.5% CI, 2.66; δNI = +6). There were
no significant differences between the genetic counselors and web-based platform detected
betweenmodes of education delivery in disclosure rates to spouses (151 vs 159; relative risk
[RR], 1.04; 95% CI, 0.64-1.69; P > .99), children (103 vs 117; RR, 1.07; 95% CI, 0.85-1.36;
P = .59), or siblings (91 vs 78; RR, 1.17; 95% CI, 0.94-1.46; P = .18).
CONCLUSIONS AND RELEVANCE This trial demonstrates noninferiority of web-based return of
carrier results among postreproductive, mostly healthy adults. Replication studies among
younger andmore diverse populations are needed to establish generalizability. Yet return of
results via a web-based platformmay be sufficient for subsets of test results, reserving
genetic counselors for return of results with a greater health threat.
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G
enomic sequencing is increasingly used by medical
practitioners in the care of their patients. Its use is
primarily in identifying the cause of rare, undiag-
nosed conditions. Yet sequencing cangeneratemultiple types
of clinically relevant results, including carrier results that pre-
dict risks to future offspring,which is information that adults
have interest in learning.1Asthis technologygains favor inclini-
cal practice, it will be challenging to uphold the standard for
test results to be returned in person by a knowledgeable
practitioner, typically a genetic counselor or medical
geneticist.2 Not only is this face-to-face encounter impracti-
cal owing to workforce limtations, but increasing use of se-
quencing will migrate into mainstream medicine and pri-
mary care practitioners have significant constraints on their
time to add discussions of multiple results. As such, less re-
source-intensive alternativedeliverymodes areneeded for re-
turnof carrier results.3Sucha resourcewouldenablemorepri-
mary care physicians to effectively use this emerging
technology.
Genetic counseling comprises 2 related but distinct
functions: the provision of genetic information4 and psy-
chological counseling about managing the threat of living at
risk.5 In the design of studies to assess independent effects
on outcomes, the education and counseling components
can be separated.6 In a recent systematic review of random-
ized clinical trials (RCTs) reporting outcomes of genetic
counseling for predictive genetic testing,7 3 studies com-
pared education by a genetic counselor with pretest educa-
tion by a web-based platform8-12 and found equivalence or
noninferiority between the intervention arms. However, to
our knowledge, no published RCTs in genetic counseling
have been reported that assessed differences following
receipt of results.
Commercial testing companies promote the use of
expanded carrier testing and have developed online plat-
forms for returning results. To our knowledge, no reports on
the evidence of the effectiveness of these interventions
have been published, particularly when compared with
clinical genetic counseling. Use of expanded carrier testing
by practitioners is increasing and, to our knowledge, no RCT
of interventions returning carrier results from exome
sequencing has been reported.
We conducted a novel RCT to return results to partici-
pants in a postreproductive exome sequencing cohort. Our
cohort expressed interest in learning their carrier results for
themselves and the benefit of their adult children.1 We
selected the return of carrier results because they were
desired and deemed low risk for adverse clinical outcomes
due to participants’ postreproductive status.
Our objectives were to evaluate the efficacy of a web-
based platform for educating patients by assessment of non-
inferiority compared with a genetic counselor and deter-
mine whether observed differences between educational
arms were affected by subsequent counseling. We hypoth-
esized that the web-based platform would be noninferior to
a genetic counselor in knowledge of recessive inheritance,




Eligible participants were primarily healthy adults from the
ClinSeqcohort13,14 (eTable 1 inSupplement 1)who (1) hadcom-
pleted a baseline survey, (2) were heterozygous for a variant
confirmedinaClinicalLaboratory ImprovementAmendments–
approved laboratory in at least 1 gene causing aphenotype in-
herited in an autosomal-recessive pattern, and (3) had not re-
ceived prior genetic test results from ClinSeq.
The National Human Genome Research Institute Institu-
tional Review Board approved this study. Participants pro-
vided informed verbal consent; they did not receive financial
compensation. CONSORT guidelines15 and the National Soci-
etyofGeneticCounselorsguidelines for reporting studieswere
used to guide preparation of this article.16The study protocol
is available in Supplement 2.
Study Design
Weused a 2 × 2 between-participant factorial design. All par-
ticipants were randomized to 1 of 4 study arms using an on-
line resource (ResearchRandomizer, version4.0,https://www
.randomizer.org/) education by web-based platform only,
education by counselor only, education by web-based plat-
form followed by genetic counseling, and education by coun-
selor followed by genetic counseling. Study flow is docu-
mented in Figure 1. Herein, we report outcomes across the
educational armsbecause randomization tocounselinghadno
effect on our primary outcomes as reported within. Analyses
of the counseling sessions are planned for later publication.
Educational Arms
The content for the educational armswasdevelopedusing ex-
isting resources on carrier status and recessive inheritance
and professional guidelines on reporting carrier results to
patients.17-21Eacheducationarmconveyed the same informa-
tion:what itmeans tobea carrier, autosomal-recessive inheri-
tance, carrier status for children and grandchildren, the par-
ticipant’spersonalcarrier results report, andtesting limitations.
Concepts were illustrated using identical visual aids in both
arms. The individualized carrier results report included infor-
mation text bubbles that defined the headings for the results
Key Points
Question Is a web-based platform noninferior to a genetic
counselor in returning carrier results from exome sequencing?
Findings In a randomized noninferiority trial of 462 adults, return
of results by a web-based platformwas noninferior to return by a
genetic counselor. Noninferiority was assessed by the lack of
significant difference in arms by 1-sided t tests of knowledge of
recessive inheritance, test-specific distress, and decisional conflict
about choosing to learn results.
Meaning Return of carrier results from exome sequencing by a
web-based platformmay be an acceptable, cost-effective
alternative to a genetic counselor.
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in the web-based platform; the counselor explained the re-
sults in theother arm.Theunique individualized risks for dis-
easeamongparticipants’ adult childrenandgrandchildren (low
in both cases but for different reasons) andmanifestations of
the conditions identified in a carrier state were described in
both educational arms. The information (absent thenames of
genetic conditions) scored at a 9.2 grade level as assessed by
the Flesch-Kincaid scale.22
Theweb-basedplatformwaspilotedwithvolunteerClinSeq
participants, and improvementsweremade to the description
of carrier status in response to interview feedback (eAppendix
inSupplement1).Giventhehigh levelofeducation inthecohort
andtheeaseofuseforthepilotparticipants,nofocusgroupswere
conducted. If theweb-basedplatformintervention isused infu-
turestudiesofmorediverseandyoungerpopulations,thereports
mayneedtobesimplifiedandassessedusingcognitiveinterview-
ing among the target population.
The education provided by the genetic counselor (one
of us, K.L.L.) was not scripted but was designed to convey
the same information as the the web-based platform. The
counselor deferred any counseling issues that arose in the
education session.
All educational sessions were audiorecorded and tran-
scribed. A total of 106 of 228 (46.5%) of the transcripts from
the genetic counselor arm were analyzed to assess whether
the major topics were addressed consistently and that ancil-
lary topics were not introduced. This approach was key to
ensuring fidelity by maintaining content similarity between
study arms.
Genetic Counseling Arm
All genetic counseling sessions were conducted by the same
genetic counselor (K.L.L.). Genetic counseling was distin-
guished from educational by considering counseling as any
Figure 1. Participant Flow
1001  Assessed for eligibility
571 Eligible participants approached for study recruitment
462 Randomized morning of in-person visit at NIH CC
234 Allocated to education via web-based platform and immediate
follow-up survey
200 Completed 1-month follow-up survey
34 Lost to follow-up (could not be contacted via telephone or mail to
complete survey)
202 Completed 6-month follow-up survey
32 Lost to follow-up (could not be contacted via telephone or mail to
complete survey)
198 Completed 1-month follow-up survey
30 Lost to follow-up (could not be contacted via telephone or mail to
complete survey)
190 Completed 6-month follow-up survey
38 Lost to follow-up (could not be contacted via telephone or mail to
complete survey)
114 Allocated to genetic counseling
and immediate follow-up survey
112 Received allocated intervention
2 Did not (1 by request,
1 misunderstood results to
be hypothetical)
120 Allocated to no genetic counseling 114 Allocated to no genetic counseling 114 Allocated to genetic counseling
and immediate follow-up survey
394 Did not meet inclusion criteria
308 No baseline survey
5 No report (not all variants confirmed)
63 No report (no variants to return)
17 Received previous result
1 No report (will not return for results; known ahead of report generation)
2 Used for piloting study
34 Baseline survey completed but not needed to reach recruitment goals
65 Declined study
36 Nonresponsive
2 Removed (spouses recognized as carriers for same gene)
3 Declined results
2 Died
1 Removed (result had personal health risk)
228 Allocated to education via genetic counselor 
and immediate follow-up survey
227 Received allocated intervention
1 Did not (received same results through outside sequencing)
A total of 1001 members of the ClinSeq cohort were assessed for eligibility for this trial. Ultimately, 462 individuals were randomized. NIH CC indicates National
Institutes of Health Clinical Center.
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participant concerns related to one’s carrier results that were
not informationbased,whichweredeffered if raised in theedu-
cation arm.
Genetic Testing Reports
Eligible variants included those in genes associated with
disorders inherited in an autosomal-recessive pattern23,24 if
there was no credible evidence of a heterozygote pheno-
type. Variants also (1) met quality cutoffs and a minor allele
frequency cutoff of 0.15 and (2) were splice-site, stop-gain,
frameshift, or missense variants previously reported in the
Human Gene Mutation Database.25 Pathogenicity assess-
ments were generated for all variants by 1 of us (J.J.J.) and
then reviewed by a panel (including several of us, K.L.L.,
J.J.J., and L.G.B.). A modified 6-point scale was used to clas-
sify variants as benign, likely benign, variant of uncertain
significance (VOUS)-low, VOUS-high, likely pathogenic, or
pathogenic based on several factors: predicted variant effect
(loss of function, missense), incidence in affected individu-
als, frequency of variant in control populations, and func-
tional data.26 Variants classified as pathogenic, likely patho-
genic, or VOUS-high were Clinical Laboratory Improvement
Amendments (CLIA) validated and reported to participants.
Participants received a CLIA report of their carrier results at
the end of their visit and a letter 1 month later.
Quantitative Outcomes
Primary trial outcomes were selected from the theory of
planned behavior and published RCTs: relevant knowledge,
test-specific distress, and decisional conflict. Secondary out-
comes included anxiety, risk worry, perceived risk, commu-
nication of results to at-risk relatives, and satisfaction. Par-
ticipants completed surveys immediately after education and
immediatelyaftercounselingbasedonrandomization, 1month
later, and 6months later. The surveys included the following
scales.
Knowledge of recessive inheritance was measured at all
points using 4 novel, true-false items. If both parents are
carriers of a mutation associated with a recessive genetic
disease, the chance that their pregnancy will be affected by
that disease is 25%; if 1 parent is a carrier of a variant in a
gene and the other is not, the chance that each of their chil-
dren is a carrier is 25%; only 25% (1 of 4) of people’s genome
sequence is inherited from their mother; and a person can
be a carrier for a disease even if no one else in the family has
the disease. Items were responded to using a 5-point
response scale coded with precedent from a validated
scale27 as 0, definitely no, probably no, and uncertain; 1,
probably yes; and 2, definitely yes. Items 2 and 3 are false
and so reverse scored. Summed total scores range from 0 to
8, with higher scores indicating greater knowledge (test-
retest reliability: r = 0.62, P < .001).
Test-specificdistresswasmeasuredat 1and6monthsusing
the distress subscale of theMultidimensional Impact of Can-
cerRiskAssessment28adaptedforgenetic test results. Six items
address the frequency with which participants have experi-
enced a distressing emotion in the past 2 weeks on a 4-point
scale: 0, never; 1, rarely; 3, sometimes; and 5, often. Summed
total scores range from 0 to 30, with higher scores indicating
greater test-specific distress (Cronbach α = 0.75).
Decisional conflict was measured at 1 and 6 months
using the Decisional Conflict Scale,29 which is a rating scale
of 15 items. Summed total scores range from 15 to 75, with
higher scores indicating greater decisional conflict about
the decision to learn one’s carrier results (Cronbach
α = 0.94).
Disclosure rates were assessed at 1 and 6 months by ask-
ing participants whether they had told their partner or
health care professional about their results. In addition, par-
ticipants were asked to indicate how many biological
daughters, sons, sisters, and brothers they had and how
many they had told of their results. Responses were
dichotomized into having told at least 1 child or sibling or
not.
Risk worry was measured at baseline and at 6 months
using a single, Likert-type item (How worried are you that
your relatives could be affected with a genetic condition
that you have passed on?) with a 7-point response scale
ranging from 1, not at all worried; to 7, extremely worried
(test-retest reliability: r = 0.35, P < .001).
Perceived risk wasmeasured at baseline and at 6months
using a single item (I feel like my relatives could be affected
by a genetic condition that I have passed on) with a Likert-
type response scale ranging from 1, strongly disagree; to 7,
strongly agree (test-retest reliability: r = 0.42, P < .001).
Anxiety was measured after education and counseling
using the short-form State-Trait Anxiety Inventory,30 which
consists of 6 itemson a4-point response scale ranging from 1,
not at all; to 4, verymuch. Summed total scores range from 6
to24,withhigher scores indicating greater anxiety (Cronbach
α = 0.80).
Satisfaction was measured at 6 months using a modified
version of the Genetic Counseling Satisfaction Scale,31which
consists of 3 items (ie, I feel better about my health after get-
tingmy result[s] back, the result session was the right length
of time, and the result sessionhelpedme to process the infor-
mationaboutmyresult[s]), allowing for responsesona4-point
scale ranging from 1, strongly disagree; to 4, strongly agree.
Summed total scores range from3 to 12,withhigher scores in-
dicating greater satisfaction (Cronbach α = 0.86).
Power Analysis
Power calculations were based on sample sizes and SDs of
the outcome measures assuming 80% power and 2-sided
hypothesis tests using a P < .05 α-level criterion. For the
immediate outcomes, the minimum detectable differences
between arms were 0.61 units in knowledge and 0.79 units
in anxiety. For the 6-month outcomes, the minimum detect-
able differences were 0.65 units in knowledge, 0.32 units in
risk worry, 0.49 units in perceived risk, and 2.11 units
in decisional conflict. The minimum detectable differences
in proportions of dichotomous outcomes at 6 months were
32.1% in distress, 31.8% for disclosure to spouses, 37.9% for
children, 43.2% for siblings, and 53.2% for health care pro-
fessionals. Power at 1 month was comparable to power at 6
months.
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Statistical Analysis
Differences between arms at baseline were assessed using χ2
analysis for categorical variables and analysis of variance for
continuous variables. The mean difference between educa-
tional arms (web-based platform vs counselor) and 1-sided
97.5% CI were calculated for 3 primary outcomes and 2 sec-
ondary outcomes to test for noninferiority, which was sup-
ported if the CI did not exceed the prespecified noninferior-
ity margin (δNI): −1 in knowledge; +1 in test-specific distress,
+6 in decisional conflict, +1 in risk worry, and +2 in anxiety.
The δNI for test-specific distress was determined based on a
published RCT12 that found significant difference in distress
(measured with the Multidimensional Impact of Cancer Risk
Assessment) between those who were and were not at in-
creased lifetime risk for type 2 diabetes; the δNI for decisional
conflict was based on a margin from a previous noninferior-
ity trial of telephone counseling32; the δNI for anxietywas de-
termined based on a published RCT33 that found no signifi-
cant differences in Spielberger State-Trait Anxiety Inventory
scores between graphic display and frequency format of life-
time risk for breast cancer and replicated in a more recent
publication.34 Without precedent to determine a δNI for the
novel knowledge scale, themargin was set at the smallest in-
cremental change on the scale (ie, a single point), which cor-
responded to approximatelyhalf an SDat baseline. For single-
item measures with categorical response scales (risk worry,
perceived risk), the margins were also set at the smallest in-
cremental change. This is a conservative approach applied in
noninferiority analyses where there is a lack of precedent in
use of a novel scale.32
For the two 1-sided t test procedure,35 the mean differ-
encebetweeneducational arms (web-basedplatformvs coun-
selor) and 95% CI were calculated to test for equivalence for
risk perception for which provision of genetics information
aims to make more accurate, but collectively not to increase
or decrease. Equivalencewas supported if the interval didnot
exceed the equivalence margin (δE): ±1 in perceived risk.
In secondaryanalyses,2-wayanalysisofvariancewasused
to assess the effect of a counseling session if significant dif-
ferencesweredetected inprimary analyses. Sensitivity analy-
ses were conducted among those with and without children
given thedifferential implications of receipt of results. Differ-
ences between arms in satisfaction and disclosure rates were
assessed using a t test and the Fisher exact test, respectively.
Analyseswere basedon available data at eachpoint, andboth
intention-to-treat andper-protocol analyseswere applied. For
outcomes exhibiting nonnormality, robustness of the find-
ingswas verifiedwithnonparametric tests. Parametric analy-
seswere conducted using SPSS,Macintosh version 20.0 (IBM
Corp), andnonparametric analyseswere conductedusing the
package36 in R with pairwise CI.
Qualitative Outcomes
Responses to theopen-endedquestion,what, if any, informa-
tion do you feel was missing from the [genetic counselor/
computer] session? were independently coded by 2 of us
(I.M.M., A.R.H.) using NVivo 11 (QSR International). Both in-
vestigators used the same codebook to analyze the responses
by thematic analysis and reconciled most discrepancies
through discussion. Intercoder reliability calculated by per-
cent agreement was 98.8% and 99.0% in the web and coun-
selor arms, respectively.
This study was conducted from February 5, 2014, to De-
cember 16,2016,andendedbecause the6-monthresponse rate
suggested that the target sample size would be achieved.
Results
Participants
All participants completedbaseline surveys assessingpsycho-
logical variables after enrollment in the ClinSeq cohort study
andbefore enrolling in thisRCT.As such, time fromtaking the
baselinesurvey toparticipation in theRCTvaried: timeelapsed
ranged from 4months to 4 years (mean [SD], 1.9 [0.7] years).
Thisdurationwasapproximatelynormallydistributedandnot
significantly associatedwith any covariates and thuswas not
contolled for in the analyses. Barring the 3 individuals ex-
cluded after randomization, all participants completed in-
trial surveys. A total of 398 (86.1%) participants returned
1-month surveys and 392 (84.8%) returned 6-month surveys;
nonresponders did not differ significantly from the 462 par-
ticipants in any demographic variables. All 462 of 571 eligible
participants (80.9%)provided informedverbal consent topar-
ticipate in the RCT.
Overall, this sample was predominantly married, well-
educated, postreproductive, and non-Hispanic white; these
characteristics were not significantly different from the full
ClinSeqcohort.13Mean(SD)ageof theparticipantswas63 (63.1)
years; other demographic and session characteristics are re-
ported in Table 1. The randomization was effective as there
were no significant differences in any variables at baseline.
Fidelity to the Intervention
Fidelity to the counselor armranged from83%to 100%(mean
[SD], 95% [5.6%]) across the 8 central topics and their subdo-
mains (eTable 2 in Supplement 1). As such, the content of the
informationconveyedinbotheducationalarmswashighlycon-
sistent with the exception of information tailored to the pa-
tient’s personal variant results, as designed.
Quantitative Outcomes
Means (SDs) of study variables by education arm are given in
Table 2. Bivariate analyses resulted in no significant differ-
ences between educational arms in any of these variables at
baseline. The web-based platform was noninferior to the ge-
netic counselor in terms of knowledge assessed immediately
after education and all primary outcomes assessed 1 month
later: knowledge, test-specific distress, and decisional con-
flict. The main analysis at 6 months yielded consistent re-
sults. There were no significant differences at 6 months be-
tweeneducational arms inknowledge (meangroupdifference,
−0.18; lower limitof97.5%CI,−0.63;δNI = −1), test-specificdis-
tress (median group difference, 0; upper limit of 97.5% CI, 0;
δNI = +1), or decisional conflict (mean group difference,
1.18; upper limit of 97.5% CI, 2.66; δNI = +6). The web-based
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platformwasalsononinferior to thegenetic counselor for anxi-
ety at the immediate follow-up and for riskworry and equiva-
lent for perceived risk at 6 months. These results are repre-
sented inFigure2. Because test-specificdistressdataexhibited
a floor effect at both 1- and6-month follow-ups, violatingnor-
mality assumptions for parametric tests, differences be-
tween educational arms were assessed with nonparametric
tests. No significant differences were detected at either time
point nor did the nonparametric CIs exceed the noninferior-
ity margin (δNI = +1), which supports the hypothesis of non-
inferiority.
Basedonanobservedstatistically significantdifferencebe-
tween the educational arms (although not clinically signifi-
cant by ourmargin for anxiety, δNI = +2), analysis of variance
testing was used to evaluate differences in anxiety immedi-
ately following counseling or no counseling, based on ran-
domization (eFigure in Supplement 1). The interaction effect
wassignificant (F1,448 = 6.94,P < .009), suggesting that thedif-
ference in anxiety between educational arms resulted from
whether counseling followed education.
All analyses were run separately for those with andwith-
out childrenand the resultswereconsistent foreachof theout-
comes except decisional conflict at 6 months: the mean dif-
ference between educational arms was 2.43 (95% CI, 0.77 to
4.09) among thosewith at least 1 child,whereas themeandif-
ferencewas−1.79 (95%CI, −5.69 to 2.12) among thosewithno
children. Thus, parents reported statistically significantly
greater decisional conflict when educated by the web-based
platform (not exceeding δNI = +6)—an effect not observed
among participants without children.
Satisfaction was high overall (mean [SD], 9.86 [2.12]) but
significantly lower in theweb-basedplatformarmat6months:
themean difference between educational armswas 1.11 (95%
CI, 0.71-1.52; P < .001). As reported in Table 3, there were no
significant differences observedbetweeneducational arms in
rate of disclosure to spouses, children, siblings, or health care
professionals at 1 or 6 months; however, the power to detect
differences was low.
Qualitative Outcomes
Immediately after the educational intervention, 174 of 225
(77.3%)participants in thecounselor armand96of 193 (49.7%)
in the web-based platform arm answered that none or noth-
ing was missing from the educational sessions. More partici-
pants fromtheweb-basedplatformarm(31of 193 [16.1%]) than
from the counselor arm (5 of 225 [2.2%]) requested addi-
tional informationspecific to their results, suchasdisease treat-
ment options, risk of disease, and testing options for family
members, aswell as the frequencyandprevalenceof theirvari-
ant in the general population.
Discussion
This study addresses a critical conundrum of clinical genom-
ics: theneed for less resource-intensive resultsdeliverymodes
apparently conflicts with the need to maintain current stan-
dards of practice. In-person delivery of individual test results
by a health care professional is the standard of care and pre-
sumed to be superior to other modes. Our data demonstrate
noninferiority of aweb-basedplatform inknowledgeof reces-
sive inheritance, test-related distress, and decisional conflict
about choosing to learn results. There are important service
delivery implications of these results as they suggest that car-
rier results can be returned to certain populations via a web-
based platform that conveys relevant information with suffi-
cient gains in knowledge and no evidence of adverse
psychological well-being. These results are consistent with
those of 3 other RCTs returning single genetic variant results
comparing in-personwithcomputer interventions.8-12Withad-
ditionalsupportingevidence, in-persongeneticcounselingmay
be reserved for individuals receiving results that are more
health threatening thancarrier results.5Given the limits of the







Dichotomous Classification, No. (%)
Sex
Male 127 (55.9) 119 (51.3)
Female 100 (44.1) 113 (48.7)
Marital status
Not in a marriage-like partnership 49 (22.2) 45 (20.3)
In a marriage-like partnership 172 (77.8) 177 (79.7)
Annual household income, $
≤100 000 52 (24.0) 53 (23.9)
>100 000 165 (76.0) 169 (76.1)
Education
<Postgraduate degree 77 (34.8) 90 (40.2)
Postgraduate degree 144 (65.2) 134 (59.8)
Race
White 215 (94.7) 211 (91.3)
Nonwhite 12 (5.3) 20 (8.7)
Ethnicity
Hispanic or Latino 2 (0.9) 7 (3.0)
Not Hispanic or Latino 224 (99.1) 223 (97.0)
Parental status
0 Children 52 (24.9) 46 (22.9)
≥1 Child 157 (75.1) 155 (77.1)
Results returned
≥1 Pathogenic 175 (77.1) 174 (75.0)
0 Pathogenic 52 (22.9) 58 (25.0)
≥1 Likely pathogenic 70 (30.8) 75 (32.3)
0 Likely pathogenic 157 (69.2) 157 (67.7)
≥1 VOUS 122 (53.7) 106 (45.7)
0 VOUS 105 (46.3) 126 (54.3)
Continuous Characteristics, Mean (SD)
Total No. of results returned,
per participant
2.4 (1.2) 2.3 (1.3)
Counseling session length, if applicable,
min
11 (6.7) 11 (7.3)
Educational session length, min 27 (9.3) 21 (10.6)
Age at intervention, y 63.2 (5.4) 63.3 (5.7)
Abbreviation: VOUS, variant of uncertain significance.
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genetics health care workforce,3 such evidence-based alter-
native delivery modes will be needed. In addition, effective
web-based tools for supporting sequencingwouldallowhealth
careprofessionals to comfortablyand responsiblyuse thisnew
technology in their practice. This evidence can alsohelp to in-
form a responsible approach to the results delivery from ge-
nomesequencing to address 1 of the challenges facedby large-
scale sequencing efforts, such as the National Institutes of
Health All of Us Research Program (https://www.nih.gov
/research-training/allofus-research-program).
Our results demonstrate that a strong interest in learn-
ing carrier results at baseline1 translated to downstream
uptake, which differs from past research8 and suggests that
participants perceived potential value of their results for
their family members. Although this sample was a well-
educated group, it remains heartening that we found no
indication of distress or other potential psychological harms
that may arise from learning one’s carrier status. Parents
randomized to the web-based platform expressed greater
decisional conflict about learning results, which is not unex-
pected in that the results pertain to risks to their grandchil-
dren. Those randomized to the web-based platform were
less satisfied with the session than were those ramdomized
to a genetic counselor. In light of the noninferiority assess-
ments for our primary outcomes and high satisfaction
scores overall, the difference may not be clinically meaning-
ful, making it difficult to justify the expense of in-person
results delivery. Yet, in response to our qualitative findings,
use of a web-based platform should include links to more
detailed information on the specific diseases identified and
risks to family members for those who desire additional
information or reinforcement of the information gained.
Limitations
Our participants are of postreproductive age and early
adopters of technology14 who are capable of articulating
areas of need and concern related to return of sequence
information. As such, results from this study may not gener-
alize to other populations. A replication study is planned for
a more diverse, newly recruited cohort. It is also important
to replicate these findings among younger adults who may
use the information for reproductive decision making.
We chose carrier results for this study because they are
common and numerous, but also because they have limited
direct health influence on our participants. This was an
important consideration for participant safety. These results
Figure 2. Noninferiority of Trial Outcomes
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Noninferiority or equivalence range
Mean group differences between educational arms (web-based
platform − genetic counselor) noted immediately after (A), 1 month after (B),
and 6months after (C) education with respect to 2 primary outcomes
(knowledge, decisional conflict) and 3 secondary outcomes (anxiety, risk worry,
risk perception). Test-specific distress is not depicted because a severe floor
effect observed at 1 and 6months rendered parametric tests inappropriate.
Noninferiority was tested for outcomes shownwith 1-sided 97.5% CIs, and
equivalence was tested for the risk perception outcomewith a 2-sided 95% CI.
The gray shaded portion denotes the noninferiority (or equivalence) range
defined by the prespecified margins (δNI or δE), which determines rejection of
the null hypothesis if not exceeded. For knowledge, the possible score was 0 to
8 (δNI = −1); anxiety, 6 to 24 (δNI = +2); decisional conflict, 15 to 75 (δNI = +6);
risk worry, 1 to 7 (δNI = +1); and risk perception, 1 to 7 (δE = ±1).




Genetic Counselor Web Platform
Baseline Immediate 1 Month 6 Months Baseline Immediate 1 Month 6 Months
Knowledge (0-8) 3.67 (2.12) 5.05 (2.06) 4.92 (2.20) 4.55 (2.31) 3.76 (2.31) 4.96 (2.26) 4.67 (2.23) 4.37 (2.27)
Test-specific
distress (0-30)b
NA NA 0.99 (2.29) 0.63 (1.79) NA NA 1.62 (3.47) 1.17 (2.76)
Decisional conflict
(15-75)
NA NA 20.57 (8.79) 20.40 (7.40) NA NA 21.00 (7.64) 21.58 (7.51)
Anxiety (6-24) NA 7.98 (2.61) NA NA NA 8.79 (2.99) NA NA
Risk worry (1-7) 2.52 (1.43) NA NA 2.15 (0.97) 2.62 (1.58) NA NA 2.25 (1.28)
Perceived risk (1-7) 3.90 (1.96) NA NA 4.35 (1.63) 3.90 (1.95) NA NA 4.28 (1.82)
Satisfaction (3-12) NA NA NA 10.43 (1.83) NA NA NA 9.32 (2.24)
Abbreviation: NA, not applicable.
a Cells labeled NA indicate that variable was not assessed at that time.
bA floor effect was observed for test-specific distress at 1 mo (median, 0;
interquartile range, 1; n = 398) and 6mo (median, 0; interquartile range, 0;
n = 390).
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are not necessarily generalizable to exome or genome
sequencing results relating to primary findings for an
underlying genetic disease or to secondary findings where
the current standard of disclosure by a genetics health care
professional should be followed.
Conclusions
Overall, our findings suggest that use of alternative delivery
modes in the return of carrier results from genome sequenc-
ing shouldbe considered in the faceof limitedprofessional re-
sources and the ever-present imperative to reducehealth care
costs. This approach could also facilitate theuseof exomeand
genome sequencing by nongenetics health care profession-
als by providing a responsible approach to routine results re-
turn that does not place high demands on the ordering clini-
cian.We speculate that similar approaches for return of other
sequencing results that arenonthreatening topersonal health
(eg, pharmacogenetics) may be appropriate. This study pro-
vides initial evidence for the effectiveness of carrier informa-
tion provision by a web-based platform in an older popula-
tion, which can support the wider use of genomic testing by
clinicians and allow genetics health care professionals to fo-
cus on more pressing clinical needs for which standard ge-
netic counseling is paramount.
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eFigure. Anxiety assessed immediately after counseling or no counseling. The contrast bars 
represent significant differences in means with respect to anxiety. Possible scores on this scale 



















eTable 1. Participant Demographics and Clinical Characteristics of Responders and 






Characteristic Dichotomous Classification n (%) n (%) 
Gender  
Male 217 (55.4) 29 (43.3) 
Female 175 (44.6) 38 (56.7) 
Marital Status 
Not in a marriage-like partnership 80 (21.2) 14 (21.5) 
In a marriage-like partnership 298 (78.8) 51 (78.5) 
Household 
Income 
Less than $100,000 per year 93 (24.8) 12 (18.7) 
More than $100,000 per year 282 (75.2) 52 (81.3) 
Education 
Less than a post-graduate degree 142 (37.4) 25 (38.5) 
Post-graduate degree 238 (62.6) 40 (61.5) 
Race 
White 364 (93.1) 62 (92.5) 
Non-white 27 (6.9) 5 (7.5) 
Ethnicity 
Hispanic or Latino 9 (2.3) 0 (0.0) 
Not Hispanic or Latino 380 (97.7) 67 (100.0) 
Parental Status 
No children 83 (23.6) 15 (25.4) 
At least one child 268 (76.4) 44 (74.6) 
Results 
Returned 
At least one “pathogenic” 292 (74.5) 57 (85.1) 
Zero “pathogenic” 100 (25.5) 10 (14.9) 
At least one “likely pathogenic” 125 (31.9) 30 (29.9) 
Zero “likely pathogenic” 267 (68.1) 47 (70.1) 
At least one “VOUS” 198 (50.5) 30 (44.8) 










1. Introduction to the RCT  
Review of genome sequencing and interpretation 95 
Description of analysis done for RCT  96 
2. Description of autosomal recessive inheritance  
Description of carrier status inproband--lack of symptoms 91 
Description of carrier status in partner/children 91 
Description of risk to grandchildren--lack of symptoms in 
healthy, adult children places focus on risks to grandchildren 
85 
Description of risk to grandchildren--both parents need to be 
carriers, both to pass on variants 
84 
3. Explaining sections of information on CLIA report  
Genomic position 92 
Pathogenicity 97 
Condition name 99 
4. Variant results; Condition description and risk information for:  
1st result 96 
2nd result 98 
3rd result 97 
4th result 97 
5th result 100 
6th result 100 
7th result 100 
5. Recommendations  
Sharing with reproductive-aged relatives 99 
Reproductive-aged relatives recommended to have genetic 
counseling, ideally preconceptually 
96 
6. Limitations  
Absence of a result does not rule out having an affected family 
member in the future 
98 
Ongoing analysis of additional genes 83 
7. Elicitation of questions by GC 87 
















Participants  will  return  to  the  NIH  CRC  in  order  to  receive  their  results.  They  will  then  be 

















disclosure  education  session.  It  will  focus  on  the  meaning  and  impact  of  the  information, 
exploration  of  plans  to  use  the  information  and  any  concerns  the  participants  may  have; 











                         
               
As  described  above, we  propose  to  conduct  a  2x2  randomized  control  to  determine  how  a 
website compares to genetic counseling in facilitating understanding of carrier status identified 
through  genomic  sequencing.  Participants will  be  given  up  to  three  surveys  as  part  of  their 
participation: 
 Intervention Survey T2  (Appendix ZF, Survey VIどa) will be given  immediately  following  the 
results disclosure session for those who are going to receive genetic counseling. The survey 
will  assess  knowledge,  understanding,  residual  questions,  and  questions  on  participants 
understanding  of  the  possibility  for  false  negative  testing  results.  The  measures  consist 
largely of previously used and validated scales, as detailed in the Appendix. This survey will 
be  administered  at  participants  clinical  visits  using  Survey Monkey,  a  surveyどdesign  and 
data collection website. Alternatively, participants can complete the survey on paper if they 
prefer. The survey is expected to take no longer than 20 minutes.  
 Intervention Survey T2  (Appendix ZF, Survey VIどb) will be given  immediately  following the 
results disclosure session for those who are not going on to receive psychosocial counseling. 
The  survey  will  assess  knowledge,  understanding,  residual  questions,  residual  concerns, 
anxiety,  satisfaction,  decisional  conflict,  learning  preferences,  and  questions  on  the 
participants understanding of the possibility for false negative testing results. The measures 
consist  largely  of  previously  used  and  validated  scales,  as  detailed  in  the Appendix.  This 
survey will be  administered  at participants  clinical  visits using  Survey Monkey, a  surveyど
design and data collection website. Alternatively, participants can complete the survey on 
paper if they prefer. The survey is expected to take no longer than 20 minutes.  
 Intervention  Survey  T3  (Appendix  ZG,  Survey  VII)  will  be  given  following  the  genetic 
counseling sessions  in  two groups, and will assess  residual concerns, anxiety, satisfaction, 
decisional  conflict,  and  preferences  for  having  additional  time with  a GC  to  process  the 
carrier results will be assessed. An openどended question will explore what added value they 
found in the second portion of the session; they will be asked to rank the importance of the 
added  value.  Identification of elements of  added benefit will be explored.  The measures 
consist  largely  of  previously  used  and  validated  scales,  as  detailed  in  the Appendix.  This 




the  visit  and  will  assess  knowledge  of  carrier  status,  understanding  of  inheritance, 
satisfaction with the intervention and decisional conflict about learning results, disclosure of 
information,  impact of  results  (MICRA) and engagement with ClinSeq. This  survey will be 
administered  online  using  Survey  Monkey,  a  surveyどdesign  and  data  collection  website. 
Alternatively, participants  can  complete  the  survey on paper  if  they prefer. The  survey  is 
expected  to  take  no  longer  than  15  minutes.  Participants  will  be  reminded  to  take  the 
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Added Text: 
 Intervention Survey T5 (Appendix ZK, Survey IX) will be given six months following the visit 
and will assess a number of  social and behavioral  constructs  related  to  return of  results. 
This  survey  will  be  administered  online  using  Survey  Monkey,  a  surveyどdesign  and  data 
collection  website.  Alternatively,  participants  can  complete  the  survey  on  paper  if  they 
prefer.  The  survey  is  expected  to  take  no  longer  than  20  minutes.  Participants  will  be 
reminded to take the survey up to three times using phone, secure medical email, mailings 
to  their  home,  or  other  approaches.
 
This trial was embedded into the ClinSeq Study (NCT00410241) and only sections of the 
protocol pertinent to this trial are included. 
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